公开(公告)号：US20230227581A1

公开(公告)日：2023-07-20

申请号：US17817334

申请日：2022-08-03

Applicant: Xencor, Inc.

Inventor： Rumana Rashid ,  Umesh S. Muchhal ,  Gregory Moore ,  Alex Nishtal ,  Seung Chu ,  Sung-Hyung Lee ,  Yoon Kyung Kim

IPC: C07K16/40 ,  C07K16/28 ,  C07K16/46 ,  C12N15/63

CPC classification number: C07K16/40 ,  C07K16/2809 ,  C07K16/468 ,  C12N15/63 ,  C07K2317/565 ,  C07K2317/622

Abstract: The present invention is directed to antibodies, including novel antigen binding domains and heterodimeric antibodies, that bind Ectonucleotide pyrophosphatase/phosphodiesterase family member 3 (ENPP3).

公开(公告)号：US20220135684A1

公开(公告)日：2022-05-05

申请号：US17501846

申请日：2021-10-14

Applicant: Xencor, Inc.

Inventor： John R. Desjarlais ,  Gregory Moore ,  Michael Hedvat ,  Juan Diaz ,  Veronica Gusti Zeng ,  Umesh S. Muchhal

IPC: C07K16/28 ,  A61K39/00

Abstract: Provided herein are novel αPD-L1 antibodies and methods of using such antibodies for the treatment of cancers. In some embodiments, the antibodies are αPD-L1×αCD28 bispecific antibodies. Such antibodies enhance anti-tumor activity by providing a costimulatory signal for T-cell activation against tumor cells while advantageously also blocking inhibitory PD-L1:PD-1 pathway interactions.

公开(公告)号：US20230041377A1

公开(公告)日：2023-02-09

申请号：US17936331

申请日：2022-09-28

Applicant: Xencor, Inc.

Inventor： Matthew Bernett ,  Gregory Moore ,  John Desjarlais ,  Michael Hedvat ,  Christine Bonzon ,  Alex Nisthal ,  Umesh S. Muchhal

IPC: C07K16/28 ,  C07K14/735 ,  C12N15/861

Abstract: The present invention is directed to heterodimeric anti-LAG-3×anti-CTLA-4. Also provided are nucleic acid compositions that encode the antibodies, expression vector compositions that include the nucleic acids, and host cells that include the expression vector compositions.

公开(公告)号：US20200317814A1

公开(公告)日：2020-10-08

申请号：US16805453

申请日：2020-02-28

Applicant: Xencor, Inc.

Inventor： Rumana Rashid ,  Umesh S. Muchhal ,  Gregory Moore ,  Alex Nisthal ,  Seung Chu ,  Sung-Hyung Lee ,  Yoon Kyung Kim

IPC: C07K16/40 ,  C07K16/46 ,  C07K16/28 ,  C12N15/63

Abstract: The present invention is directed to antibodies, including novel antigen binding domains and heterodimeric antibodies, that bind Ectonucleotide pyrophosphatase/phosphodiesterase family member 3 (ENPP3).

公开(公告)号：US11492407B2

公开(公告)日：2022-11-08

申请号：US16435375

申请日：2019-06-07

Applicant: Xencor, Inc.

Inventor： Matthew Bernett ,  Gregory Moore ,  John Desjarlais ,  Michael Hedvat ,  Christine Bonzon ,  Alex Nisthal ,  Umesh S. Muchhal

IPC: C07K16/28 ,  C07K14/735 ,  C12N15/861 ,  A61K39/00 ,  A61P35/00

Abstract: The present invention is directed to heterodimeric anti-LAG-3×anti-CTLA-4. Also provided are nucleic acid compositions that encode the antibodies, expression vector compositions that include the nucleic acids, and host cells that include the expression vector compositions.

公开(公告)号：US11472890B2

公开(公告)日：2022-10-18

申请号：US16805453

申请日：2020-02-28

Applicant: Xencor, Inc.

Inventor： Rumana Rashid ,  Umesh S. Muchhal ,  Gregory Moore ,  Alex Nisthal ,  Seung Chu ,  Sung-Hyung Lee ,  Yoon Kyung Kim

IPC: C07K16/40 ,  C07K16/28 ,  C07K16/46 ,  C12N15/63

Abstract: The present invention is directed to antibodies, including novel antigen binding domains and heterodimeric antibodies, that bind Ectonucleotide pyrophosphatase/phosphodiesterase family member 3 (ENPP3).

公开(公告)号：US20140205605A1

公开(公告)日：2014-07-24

申请号：US13794676

申请日：2013-03-11

Applicant: XENCOR, INC.

Inventor： Matthew J. Bernett ,  John R. Desjarlais ,  Sher Bahadur Karki ,  Gregory Alan Lazar ,  Umesh S. Muchhal ,  Duc-Hanh Thi Nguyen ,  John O. Richards

IPC: C07K16/28 ,  A61K39/395 ,  A61K31/573 ,  A61K31/69 ,  A61K31/454

CPC classification number: C07K16/2896 ,  A61K31/454 ,  A61K31/573 ,  A61K31/69 ,  A61K39/3955 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/72 ,  C07K2317/92

Abstract: The present disclosure describes antibodies that target HM1.24. In various aspects, the antibodies have specific CDR, variable, or full length sequences, have modifications with the parent antibody, or include at least one modification relative to a parent antibody that alters affinity to an FcγR or alters effector function as compared to the parent antibody. Nucleic acids encoding the antibodies and methods of using the antibodies are also disclosed.

Abstract translation: 本公开描述了靶向HM1.24的抗体。 在各个方面，抗体具有特异性CDR，可变或全长序列，与亲本抗体具有修饰，或者相对于亲本抗体，相对于母体抗体，包括改变对FcγR的亲和力或改变效应子功能的亲本抗体的至少一个修饰 抗体。 还公开了编码抗体的核酸和使用抗体的方法。